Dihydro Related Published Studies
Well-designed clinical trials related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)
13,14-Dihydro-15-keto prostaglandin F2alpha release in response to oxytocin challenge early post-partum in anoestrous Nelore cows submitted to temporary calf removal and progesterone priming. [2010.10]
Luteal blood flow and concentrations of circulating progesterone and other hormones associated with a simulated pulse of 13,14-dihydro-15-keto-prostaglandin F2alpha in heifers. [2010.03]
An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing. [2009.03]
Well-designed clinical trials possibly related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and
moxifloxacin combinations: a randomised trial. [2012]
Delamanid for multidrug-resistant pulmonary tuberculosis. [2012]
Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in
healthy Korean male volunteers: single- and multiple-dose randomized,
placebo-controlled studies. [2012]
Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. [2011.07]
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]
The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. [2011.05]
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. [2011.05]
EuroQol (EQ-5D) health utility scores for patients with migraine. [2011.05]
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study. [2011.03]
Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. [2011.02]
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. [2011.01]
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. [2011.01]
Antimigraine efficacy of telcagepant based on patient's historical triptan response. [2011.01]
Randomized, double-blind, phase II, multicenter study evaluating the
safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared
with linezolid for treatment of acute bacterial skin and skin structure
infection. [2011]
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation
in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients
with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. [2011]
Randomized, controlled trial of telcagepant over four migraine attacks. [2010.12]
Supplementation with a combination of antioxidants does not affect glycaemic control, oxidative stress or inflammation in type 2 diabetes subjects. [2010.12]
Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. [2010.12]
Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study. [2010.11]
n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study. [2010.10]
Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. [2010.09]
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. [2010.09]
A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. [2010.09]
Intrapulse changes in progesterone and LH concentrations and luteal blood flow during an estradiol-induced pulse of a metabolite of prostaglandin F2alpha in heifers. [2010.08]
Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. [2010.06]
Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. [2010.05]
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. [2010.04.01]
The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. [2010.04]
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. [2010.03]
Differential luteolytic function between the physiological breeding season, autumn transition and persistent winter cyclicity in the mare. [2010.02]
Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). [2010.01]
Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. [2010.01]
Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. [2009.11]
Randomized, controlled trial of telcagepant for the acute treatment of migraine. [2009.09.22]
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. [2009.09]
Elevated progesterone concentrations enhance prostaglandin F2alpha synthesis in dairy cows. [2009.08]
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. [2009.08]
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. [2009.07.24]
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. [2009.07]
Effect of peripartum dietary energy supplementation of dairy cows on metabolites, liver function and reproductive variables. [2009.06]
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. [2009.05]
Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis. [2009.05]
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. [2009.03]
Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction. [2009.02]
Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. [2009.02]
Nuclear oxidative damage correlates with poor survival in colorectal cancer. [2009.01.27]
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. [2008.12.20]
Effect of level of dietary n-3 polyunsaturated fatty acid supplementation on systemic and tissue fatty acid concentrations and on selected reproductive variables in cattle. [2008.09.01]
Pharmacokinetic study of clazuril (Appertex) in eggs and plasma from laying hens after single or multiple treatments, using a new HPLC method for detection. [2008.09]
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. [2008.09]
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. [2008.08]
Immunological and metabolic effects of cis-9, trans-11-conjugated linoleic acid in subjects with birch pollen allergy. [2008.07]
Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food. [2008.05]
Intrauterine infusion of BQ-610, an endothelin type A receptor antagonist, delays luteolysis in dairy heifers. [2008.05]
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. [2008.04.15]
Correlation between two markers of inflammation, serum C-reactive protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease. [2008.02]
Bioequivalence study of two tablet formulations of sildenafil. [2008]
Impact of multiple genetic polymorphisms on effects of a 4-week blueberry juice intervention on ex vivo induced lymphocytic DNA damage in human volunteers. [2007.08]
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. [2007.08]
Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers? [2007.07]
Fatty acid composition of plasma, medial basal hypothalamus, and uterine tissue in primiparous beef cows fed high-linoleate safflower seeds. [2007.06]
Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. [2007.05]
Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria. [2007.03]
Time course and attenuation of ischaemia-reperfusion induced oxidative injury by propofol in human renal transplantation. [2007]
Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70. [2007]
Other research related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)
Effect of dose of estradiol-17beta on prominence of an induced 13,14-dihydro-15-keto-PGF(2alpha) (PGFM) pulse and relationship of prominence to progesterone, LH, and luteal blood flow in heifers. [2011.08]
Mixture of cis-3-hexenol and trans-2-hexenal attenuates behavioral and stress responses induced by 2,5-dihydro-2,4,5-trimethylthiazoline and electric footshock stress in rats. [2011.07.06]
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. [2011.05.15]
Synthesis and anticonvulsant activity of 8-alkoxy-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-1-one derivatives. [2011.04]
Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats. [2010.12]
Bioengineering functional copolymers. XIV. Synthesis and interaction of poly(N-isopropylacrylamide-co-3,4-dihydro-2H-pyran-alt-maleic anhydride)s with SCLC cancer cells. [2010.11.15]
Synthesis and nootropic activity of some 2,3-dihydro-1H-isoindol-1-one derivatives structurally related with piracetam. [2010.11]
Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: synthesis and pharmacological evaluation. [2010.11]
Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold. [2010.10.01]
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents. [2010.09]
Traffic air pollution and oxidatively generated DNA damage: can urinary 8-oxo-7,8-dihydro-2-deoxiguanosine be considered a good biomarker? A meta-analysis. [2010.09]
Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. [2010.08.12]
Design and synthesis of 10-alkoxy-5, 6-dihydro-triazolo[4,3-d]benzo[f][1,4]oxazepine derivatives with anticonvulsant activity. [2010.07]
Leishmania donovani: oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. [2010.07]
Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists. [2010.07]
9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol, from Eulophia ochreata, inhibits inflammatory signalling mediated by Toll-like receptors. [2010.07]
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. [2010.05.13]
Chronic exposure to cadmium and arsenic strongly influences concentrations of 8-oxo-7,8-dihydro-2'-deoxyguanosine in urine. [2010.05.01]
Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a noninvasive biomarker of oxidative stress. [2010.04]
Urine 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a specific marker of oxidative stress, using direct, isocratic LC-MS/MS: Method evaluation and application in study of biological variation in healthy adults. [2010.03]
2-(3,4-Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities. [2010.02.15]
Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance. [2009.12.21]
Dihydropyridines decrease X-ray-induced DNA base damage in mammalian cells. [2009.12.01]
Effects of 7,8-dihydro-8-oxo-deoxyguanosine on antigen challenge in ovalbumin-sensitized mice may be mediated by suppression of Rac. [2009.12]
Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety. [2009.11.12]
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. [2009.09.24]
Behavioral effects and pattern of brain c-fos mRNA induced by 2,5-dihydro-2,4,5-trimethylthiazoline, a component of fox feces odor in GAD67-GFP knock-in C57BL/6 mice. [2009.09.14]
3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload. [2009.09]
Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats. [2009.08.15]
Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. [2009.08]
Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate. [2009.07.23]
Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice. [2009.07.23]
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. [2009.05.14]
|
